November 23, 2025 – BiotechReporter.news
Psyence Biomedical (PSYN), a Canadian-listed psychedelics company, announced it has secured pharmaceutical-grade ibogaine supply for use in global clinical trials. The development marks a significant milestone for the firm as it advances research into psychedelic-assisted therapies for addiction treatment.
Ibogaine, a naturally occurring psychoactive compound, has long been studied for its potential to interrupt substance dependency. Psyence’s ability to source ethically produced, pharmaceutical-grade material positions the company at the forefront of clinical development in this niche but promising field.
The announcement comes at a time when investor interest in psychedelics is accelerating, driven by regulatory momentum in the United States and Europe. Psyence’s supply agreement ensures that its upcoming trials meet stringent ethical and pharmaceutical standards, a critical factor for eventual regulatory approval.
Market analysts note that Psyence’s progress could attract institutional investors seeking exposure to the next wave of biotech innovation. While the psychedelics sector remains speculative, companies like Psyence are carving out leadership positions by securing supply chains and advancing clinical programs.
Shares of PSYN have traded actively on Canadian markets, reflecting growing investor appetite for psychedelic equities. The company’s latest milestone underscores the sector’s potential to deliver both medical breakthroughs and market opportunities.
